logo
Twitter
Discord
Email
logo
Doximity, Inc.

Doximity, Inc.

NYSE•DOCS
CEO: Mr. Jeffrey A. Tangney
Sector: Healthcare
Industry: Medical - Healthcare Information Services
Listing Date: 2021-06-24
Doximity, Inc. operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with digital tools built for medicine, that enables its members to collaborate with colleagues, stay up to date with the latest medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits. It primarily serves physicians, nurse practitioners, physician assistants, medical students, pharmaceutical manufacturers, and healthcare systems. The company was formerly known as 3MD Communications, Inc. and changed its name to Doximity, Inc. in June 2010. Doximity, Inc. was incorporated in 2010 and is headquartered in San Francisco, California.
Contact Information
500 3rd Street, Suite 510, San Francisco, CA, 94107, United States
650-549-4330
www.doximity.com
Market Cap
$11.99B
P/E (TTM)
51.2
52
Dividend Yield
--
52W High
$85.21
52W Low
$41.82
52W Range
51%
5.1
F-Score
Modified Piotroski Analysis
Based on 7-year fundamentals
Average • 5.1 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2018-2024

Financial Dashboard

Q1 2026 Data

Revenue

$145.91M+15.19%
4-Quarter Trend

EPS

$0.28+27.27%
4-Quarter Trend

FCF

$60.14M+52.09%
4-Quarter Trend

2026 Q1 Earnings Highlights

Key Highlights

Revenue Growth Strong Revenue reached $145.91 M, up 15%; subscription revenue increased $17.9 M compared to the prior year period.
Net Income Margin Rises Net income $53.32 M, margin improved to 37% versus 33% in prior year comparison period, showing profitability gains.
Operating Cash Flow Jumps Operating cash flow $62.101 M, showing $20.858 M increase from the prior year period, supporting liquidity needs.
EBITDA Margin Expansion Adjusted EBITDA margin expanded to 55% from 52%, reflecting strong operational leverage achieved during the quarter.

Risk Factors

Ongoing Securities Litigation Company faces multiple shareholder derivative lawsuits regarding user count disclosures; outcome remains unpredictable at this early stage.
Asset Base Declining Total assets decreased to $1.204 B from $1.264 B last quarter, primarily due to cash usage in financing activities.
Stock Repurchase Activity Significant cash used for share repurchases totaling $122.355 M this quarter, impacting immediate cash reserves available.
Interest Rate Sensitivity Hypothetical 100 basis point rate increase could decrease investment market value by $5.0 M as of June 30, 2025.

Outlook

Recent Strategic Acquisition Executed definitive agreement in July 2025 to acquire Pathway Medical Inc. for $26 M cash consideration.
Future Equity Incentives Approved $30 M equity award pool in July 2025, granting $20 M worth of PSUs subject to performance vesting.
Sufficient Liquidity Expected Existing cash and marketable securities of $841.0 M expected to support working capital requirements for next 12 months.
Tax Law Evaluation Ongoing Evaluating impact of recently enacted Tax Act on future cash taxes; currently not expecting material impact on tax expense.

Peer Comparison

Revenue (TTM)

Universal Health Services, Inc.UHS
$16.99B
+10.2%
Baxter International Inc.BAX
$11.02B
-6.3%
Encompass Health CorporationEHC
$5.80B
+11.1%

Gross Margin (Latest Quarter)

Universal Health Services, Inc.UHS
100.0%
+9.8 pp
Neurocrine Biosciences, Inc.NBIX
98.2%
-0.5 pp
Doximity, Inc.DOCS
89.2%
-0.1 pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
NBIX$15.29B35.715.8%10.0%
UHS$14.51B10.720.0%30.6%
COO$13.74B33.95.0%20.0%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
+2.2%
Moderate Growth
4Q Net Income CAGR
+6.5%
Profitability Improving
Cash Flow Stability
100%
Strong Cash Flow

Research & Insights

Reports
All Years

  • Form 10-Q - Q1 2026

    Period End: Jun 30, 2025|Filed: Aug 7, 2025|
    Revenue: $145.91M+15.2%
    |
    EPS: $0.28+27.3%
    Miss

  • Form 10-K - FY 2025

    Period End: Mar 31, 2025|Filed: May 20, 2025|
    Revenue: $570.40M+20.0%
    |
    EPS: $1.19+52.6%
    Beat

  • Form 10-Q - Q3 2025

    Period End: Dec 31, 2024|Filed: Feb 6, 2025|
    Revenue: $168.60M+24.6%
    |
    EPS: $0.40+53.8%
    Beat

  • Form 10-Q - Q2 2025

    Period End: Sep 30, 2024|Filed: Nov 7, 2024|
    Revenue: $136.83M+20.4%
    |
    EPS: $0.24+50.0%
    Miss

  • Form 10-Q - Q1 2025

    Period End: Jun 30, 2024|Filed: Aug 8, 2024|
    Revenue: $126.68M+16.8%
    |
    EPS: $0.22+46.7%
    Meet

  • Form 10-K - FY 2024

    Period End: Mar 31, 2024|Filed: May 23, 2024|
    Revenue: $475.42M+13.5%
    |
    EPS: $0.78+34.5%
    Beat

  • Form 10-Q - Q3 2024

    Period End: Dec 31, 2023|Filed: Feb 8, 2024|
    Revenue: $135.28M+17.4%
    |
    EPS: $0.26+52.9%
    Beat

  • Form 10-Q - Q2 2024

    Period End: Sep 30, 2023|Filed: Nov 9, 2023|
    Revenue: $113.61M+11.2%
    |
    EPS: $0.16+14.3%
    Miss